L26/P-658 Enhanced clinical utility of whole-exome sequencing–based preimplantation genetic testing for high-resolution comprehensive chromosome screening of human embryos
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von F. Fiorentino und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does whole-exome sequencing (WES)–based preimplantation genetic testing for aneuploidy (WES-PGT-A) provide an accurate and clinically useful approach for comprehensive chromosomal profiling of human embryos? Summary answer WES-PGT-A accurately detected aneuploidy and mosaicism, and additionally identified triploidy, microdeletion/duplication syndromes and de novo pathogenic variants, thereby expanding clinically embryo assessment beyond standard PGT-A. What is known already Conventional PGT-A using low-pass next-generation sequencing (NGS) reliably detects chromosomal aneuploidies; however, its limited resolution precludes accurate determination of ploidy status (i.e. numerical abnormalities affecting an entire chromosome set) and identification of clinically relevant submicroscopic copy-number variants (CNVs), including microdeletion/microduplication syndromes. Moreover, standard workflows do not interrogate single-nucleotide variants, leaving de novo pathogenic variants undetected. Transfer of embryos carrying these abnormalities may increase the risk of miscarriage, molar pregnancy and severe neurodevelopmental disorders. An integrated strategy combining high-resolution CNV analysis with ploidy assessment and variant screening could overcome these limitations and provide additional clinically actionable insight into embryo genomic constitution. Study design, size, duration This prospective study assessed the feasibility and incremental diagnostic yield of high-coverage WES-PGT-A compared with standard low-pass NGS-based PGT-A in a cohort of 126 couples undergoing IVF with indications for PGT-A between November 2023 to December 2025. The primary endpoint was concordance of chromosomal copy-number results between methods; secondary endpoints were the frequency and type of additional clinically relevant findings uniquely detected by WES-PGT-A. Participants/materials, setting, methods Overall, 517 blastocyst-stage embryos were biopsied and whole-genome amplification was performed on DNA from trophectoderm cells. Each sample was analysed in parallel using standard low-pass NGS-based PGT-A and a high-coverage WES-based workflow. A custom bioinformatics pipeline, tailored to WES data generated from trophectoderm biopsies, enabled simultaneous identification of whole-chromosome and segmental aneuploidies, mosaicism and ploidy status, as well as small pathogenic CNVs (including clinically relevant microdeletion/microduplication syndromes), together with screening for de novo single-nucleotide variants. Main results and the role of chance Conclusive paired results were obtained for 505/517 embryos (97.7%). WES-PGT-A showed complete concordance with standard low-pass NGS-based PGT-A for chromosomal copy-number profiling (505/505; 100%; 95% CI 99.3–100.0%). The WES-based workflow consistently detected whole-chromosome aneuploidies, segmental imbalances ≥5 Mb, and mosaic CNVs, with a mosaic detection threshold of ∼20% aneuploid cell fraction. These data support analytical equivalence with conventional PGT-A for routine aneuploidy classification, while enabling broader genomic interrogation. Importantly, WES-PGT-A identified additional clinically relevant abnormalities not detected by conventional PGT-A, including triploidy in 6 embryos (1.2%) and pathogenic CNVs consistent with established microdeletion/microduplication syndromes in 5 embryos (1.0%), with the smallest event measuring 900 kb, underscoring the added value of ploidy determination and higher-resolution CNV assessment. Beyond copy-number alterations, WES-PGT-A detected de novo pathogenic variants in 7 embryos (1.4%) associated with severe early-onset genetic disorders. All additional findings were confirmed by orthogonal testing, supporting their interpretation as true biological events rather than technical artefacts. Collectively, these results highlight residual risk after standard PGT-A and the potential clinical value of an integrated exome-based strategy. Limitations, reasons for caution As a single-workflow prospective study, these findings require replication across centres and analytical platforms to confirm reproducibility and refine incidence estimates for ploidy abnormalities and microdeletion/microduplication syndromes in preimplantation embryos. Randomised non-selection trials and other outcome-driven studies are needed to determine whether expanded genomic assessment translates into improved reproductive outcomes. Wider implications of the findings WES-PGT-A represents an accurate, high-resolution approach to comprehensive embryo screening. By enabling ploidy determination and detection of clinically relevant submicroscopic CNVs and de novo single-nucleotide variants alongside standard aneuploidy assessment, it broadens PGT-A scope and may reduce the residual risk of transferring embryos affected by severe chromosomal or genetic disorders. Trial registration number No
Zitieren
APA
Fiorentino, F., Pantos, K., Kokkali, G., Greco, E., Listorti, I., Pantou, A., Nuccitelli, A., Pagano, I., & Gianaroli, L. (2026). L26/P-658 Enhanced clinical utility of whole-exome sequencing–based preimplantation genetic testing for high-resolution comprehensive chromosome screening of human embryos. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.988
Vancouver
Fiorentino F, Pantos K, Kokkali G, Greco E, Listorti I, Pantou A, et al. L26/P-658 Enhanced clinical utility of whole-exome sequencing–based preimplantation genetic testing for high-resolution comprehensive chromosome screening of human embryos. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.988
BibTeX
@article{Fiorentino2026,
author = {Fiorentino, F. and Pantos, K. and Kokkali, G. and Greco, E. and Listorti, I. and Pantou, A. and Nuccitelli, A. and Pagano, I. and Gianaroli, L.},
title = {L26/P-658 Enhanced clinical utility of whole-exome sequencing–based preimplantation genetic testing for high-resolution comprehensive chromosome screening of human embryos},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.988}
}
EUVIMED